{
  "docId": "019de515-df71-7068-a98d-cc2a99c8892d",
  "docSlug": "c88233ba648814c9f5b65afc1926df6d",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 11,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/5",
  "deckHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d",
  "deckJsonHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json",
  "deckAnchorHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.58,
        "w": 0.45,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Vaccine effectiveness against COVID-19-associated hospitalizations after bivalent booster compared with no vaccination²",
      "attrs": {
        "data_points": [
          {
            "x": "7-59 days post bivalent booster",
            "y": 62,
            "series": "Immunocompetent"
          },
          {
            "x": "7-59 days post bivalent booster",
            "y": 28,
            "series": "Immunocompromised"
          },
          {
            "x": "120-179 days post bivalent booster",
            "y": 24,
            "series": "Immunocompetent"
          },
          {
            "x": "120-179 days post bivalent booster",
            "y": 13,
            "series": "Immunocompromised"
          }
        ],
        "series_names": [
          "Immunocompetent",
          "Immunocompromised"
        ],
        "x_axis_label": "Time post bivalent booster",
        "y_axis_label": "Vaccine effectiveness (%)"
      },
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40727c80-c066-4e6e-800a-6d517c31b624",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.58,
        "w": 0.45,
        "x": 0.045,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Seroconversion rates (detectable Abs) in immunocompromised people vs. immunocompetent controls after two COVID-19 vaccine doses¹ [pre-Omicron]",
      "attrs": {
        "data_points": [
          {
            "x": "Haematological cancers",
            "y": 98,
            "series": "Immunocompetent"
          },
          {
            "x": "Haematological cancers",
            "y": 62,
            "series": "Immunocompromised"
          },
          {
            "x": "Organ Transplant",
            "y": 98,
            "series": "Immunocompetent"
          },
          {
            "x": "Organ Transplant",
            "y": 43,
            "series": "Immunocompromised"
          },
          {
            "x": "Immune-Mediated Inflammatory Disorders",
            "y": 98,
            "series": "Immunocompetent"
          },
          {
            "x": "Immune-Mediated Inflammatory Disorders",
            "y": 74,
            "series": "Immunocompromised"
          }
        ],
        "series_names": [
          "Immunocompetent",
          "Immunocompromised"
        ],
        "x_axis_label": "Condition",
        "y_axis_label": "Seroconversion rates (%)"
      },
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a53ffd0e-b021-4282-8fe9-c60c76b5e4a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.045,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Immunocompromised people are less likely to have detectable SARS-CoV-2 antibodies following vaccination than immunocompetent people",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "815aaed6-4af0-4cc2-acb8-9eb6e330cae1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.53,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Immunocompromised people generate less protection against severe outcomes than immunocompetent people after bivalent boosters",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fef252bc-4446-4b40-a06c-d1f002e92a6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.91,
        "x": 0.045,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: 1. Lee BMJ 2022; 2. Centers for Disease Control and Prevention, Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023; Abs, antibodies",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d56a4023-de8c-479e-b352-62713fdb3064",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.915,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED RESPONSE TO VACCINES AND HAVE LESS PROTECTION AGAINST SEVERE COVID-19 OUTCOMES",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5fe6a10-5ee7-486d-8897-4f2b86c6468a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 3,
      "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 6,
      "from": 5,
      "beatId": "9267716b-6700-4ffc-8701-d4f03cee81cc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 5-6 further emphasize the impaired response to vaccines and waning vaccine effectiveness.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4ce340fa-5923-4426-abff-c930e25c323b",
      "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.",
      "position": 0,
      "objective": "What is the cost of not addressing the urgent need for new therapeutics?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}